| scholarly article | Q13442814 |
| editorial | Q871232 |
| P6179 | Dimensions Publication ID | 1101351785 |
| P356 | DOI | 10.1186/S13046-018-0702-X |
| P8608 | Fatcat ID | release_diiyy6x6uzagbjjwyrmgjtlw2a |
| P932 | PMC publication ID | 5838869 |
| P698 | PubMed publication ID | 29506529 |
| P50 | author | Patrizio Giacomini | Q38642656 |
| Gennaro Ciliberto | Q38800176 | ||
| Matteo Allegretti | Q57028580 | ||
| Laura Conti | Q57070565 | ||
| P2093 | author name string | Alessandra Fabi | |
| Edoardo Pescarmona | |||
| Simonetta Buglioni | |||
| Aline Martayan | |||
| P2860 | cites work | From human genome to cancer genome: the first decade | Q26827640 |
| Implementing Genome-Driven Oncology | Q30235979 | ||
| Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials | Q30783484 | ||
| Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology | Q35584856 | ||
| Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing | Q36376718 | ||
| BRCAness revisited | Q38699280 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 47 | |
| P577 | publication date | 2018-03-05 | |
| P1433 | published in | Journal of Experimental & Clinical Cancer Research | Q13739415 |
| P1476 | title | Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations | |
| P478 | volume | 37 |
| Q99614738 | Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities |
| Q92659409 | Clinical metagenomics |
| Q92088041 | Cross-sectional analysis of circulating tumor DNA in primary colorectal cancer at surgery and during post-surgery follow-up by liquid biopsy |
| Q92442367 | Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study |
| Q90079807 | From single gene analysis to single cell profiling: a new era for precision medicine |
| Q91650557 | Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies |
| Q96765678 | Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q92669193 | Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital |
Search more.